

## Supplementary

**Table S1** Details of drug compounds used in this study and their normalized concentrations

| Compound name | Supplier | Cat. No. | Actual concentration when the normalized concentration is 1 (µM) | Maximum concentration for drug test (µM) |
|---------------|----------|----------|--|--|
| Osimertinib   | MCE      | HY-15772 | 2  | 8  |
| Dabrafenib    | MCE      | HY-14660 | 2  | 8  |
| Trametinib    | MCE      | HY-10999 | 0.2  | 0.8                                      |
| Vemurafenib   | MCE      | HY-12057 | 2  | 8  |
| Encorafenib   | MCE      | HY-15605 | 2  | 8  |
| Pemetrexed    | MCE      | HY-10820 | 75   | 300                                      |
| Carboplatin   | MCE      | HY-17393 | 12.5   | 50                                       |